---
title: "Ibrance (palbociclib), all indications: Safety questions"
description: "Safety questions on Ibrance (palbociclib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Safety management, Warnings, Side effects, and Monitoring. Questions: Which infection or low blood count symptoms should Ibrance patients report? What are the warnings and precautions for Ibrance? Does Ibrance have any contraindications? Have blood clots (venous thromboembolism) been reported with Ibrance? 5 further questions follow. 9 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/ibrance/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ibrance (palbociclib), all indications: Safety questions

Manufacturer: Pfizer Laboratories Div Pfizer Inc  
Prescribing information: [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921), [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191)  
Indication pages: [HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)

## Safety management

<a id="ibrance-infection-symptoms"></a>

### Which infection or low blood count symptoms should Ibrance patients report?

> “Advise patients to immediately report any signs or symptoms of myelosuppression or infection, such as fever, chills, dizziness, shortness of breath, weakness, or any increased tendency to bleed and/or to bruise [see Warnings and Precautions (5.1)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Advise%20patients%20to%20immediately%20report,%5Bsee%20Warnings%20and%20Precautions%20%285.1%29%5D.)

## Warnings

<a id="ibrance-warnings"></a>

### What are the warnings and precautions for Ibrance?

> “WARNINGS AND PRECAUTIONS
> •
> Neutropenia: Monitor complete blood count prior to start of IBRANCE therapy and at the beginning of each cycle, as well as on Day 15 of the first 2 cycles, and as clinically indicated. (2.2, 5.1)
> •
> Interstitial Lung Disease (ILD)/Pneumonitis: Severe and fatal cases of ILD/pneumonitis have been reported. Monitor for pulmonary symptoms of ILD/pneumonitis. Interrupt IBRANCE immediately in patients with suspected ILD/pneumonitis. Permanently discontinue IBRANCE if severe ILD/pneumonitis occurs. (5.2)
> •
> Embryo-Fetal Toxicity: IBRANCE can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. (5.3, 8.1, 8.3)”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=WARNINGS%20AND%20PRECAUTIONS,effective%20contraception.%20%285.3%2C%208.1%2C%208.3%29)

<a id="ibrance-contraindications"></a>

### Does Ibrance have any contraindications?

> “4 CONTRAINDICATIONS
>
> None.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=the%20other%20side.-,4%20CONTRAINDICATIONS,None.)

## Side effects

<a id="ibrance-blood-clots"></a>

### Have blood clots (venous thromboembolism) been reported with Ibrance?

> “The following adverse reaction has been reported following administration of IBRANCE: venous thromboembolism.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=The%20following%20adverse%20reaction%20has,administration%20of%20IBRANCE%3A%20venous%20thromboembolism.)

<a id="ibrance-postmarketing-side-effects"></a>

### What Ibrance side effects were reported after approval?

> “The following adverse reactions have been identified during post-approval use of IBRANCE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
>
> Respiratory Disorders: Interstitial lung disease (ILD)/non-infectious pneumonitis
>
> Skin and Subcutaneous Tissue Disorders: Palmar-plantar erythrodysesthesia syndrome (PPES)”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=The%20following%20adverse%20reactions%20have,Disorders%3A%20Palmar%2Dplantar%20erythrodysesthesia%20syndrome%20%28PPES%29)

## Safety

<a id="ibrance-qt-interval"></a>

### Does Ibrance affect the QT interval?

> “The effect of palbociclib on the QT interval corrected for heart rate (QTc) was evaluated using time-matched electrocardiograms (ECGs) evaluating the change from baseline and corresponding pharmacokinetic data in 77 patients with breast cancer. Palbociclib had no large effect on QTc (i.e., >20 ms) at 125 mg once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=The%20effect%20of%20palbociclib%20on,complete%20cycle%20of%2028%20days.)

> “In a QTc substudy of 77 patients from PALOMA-2, no large effect (>20 ms) on the QTc interval was observed in patients taking IBRANCE<sup>1-3</sup>”

Source: [IBRANCE: Dose Monitoring During Treatment, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/monitoring#:~:text=In%20a%20QTc%20substudy%20of,was%20observed%20in%20patients%20taking)

> “In this substudy, the mean change from baseline for QTc was <8 ms with IBRANCE at all postbaseline time points in the QTc assessment period vs <7 ms in the control arm<sup>3</sup>”

Source: [IBRANCE: Dose Monitoring During Treatment, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/monitoring#:~:text=In%20this%20substudy%2C%20the%20mean,%3C7%20ms%20in%20the%20control)

<a id="ibrance-tablets-vs-capsules-side-effects"></a>

### Do Ibrance tablets and capsules differ in side effects?

> “The efficacy and safety data in the tablet label are based on the clinical trials conducted with the capsule formulation. The benefit and risk profile of IBRANCE tablets is expected to be similar to that of the capsules.<sup>1,2</sup>”

Source: [IBRANCE: Tablets & Capsules, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/tablets-capsules#:~:text=The%20efficacy%20and%20safety%20data,similar%20to%20that%20of%20the)

## Monitoring

<a id="ibrance-blood-count-monitoring"></a>

### How often are blood counts checked during Ibrance treatment?

> “Monitor CBCs prior to the start of IBRANCE therapy, on Days 1 and 15 of the first 2 cycles, on Day 1 of subsequent cycles, and as clinically indicated<sup>1,2</sup>”

Source: [IBRANCE: Dose Monitoring During Treatment, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/monitoring#:~:text=Monitor%20CBCs%20prior%20to%20the,subsequent%20cycles%2C%20and%20as%20clinically)

> “The frequency of CBC monitoring can decrease over time<sup>1,2</sup>”

Source: [IBRANCE: Dose Monitoring During Treatment, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/monitoring#:~:text=The%20frequency%20of%20CBC%20monitoring%20can%20decrease%20over)

> “For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles, monitor CBCs for subsequent cycles every 3 months, prior to the beginning of a cycle, and as clinically indicated.”

Source: [IBRANCE: Dose Monitoring During Treatment, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/monitoring#:~:text=For%20patients%20who%20experience%20a,cycle%2C%20and%20as%20clinically%20indicated.)

> “When scheduling Day 15 monitoring and subsequent follow-up visits, remember to consider when the patient actually receives their medication and initiates each cycle.”

Source: [IBRANCE: Dose Monitoring During Treatment, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/monitoring#:~:text=When%20scheduling%20Day%2015%20monitoring,medication%20and%20initiates%20each%20cycle.)

<a id="ibrance-ecg-liver-monitoring"></a>

### Does Ibrance require ECG or liver enzyme monitoring?

> “ECG, serum electrolyte, or liver enzyme tests are not required in the current IBRANCE Prescribing Information<sup>1,2</sup>”

Source: [IBRANCE: Dose Monitoring During Treatment, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/monitoring#:~:text=ECG%2C%20serum%20electrolyte%2C%20or%20liver,in%20the%20current%20IBRANCE%20Prescribing)

> “Additional monitoring may be necessary based on the individual patient<sup>1,2</sup>”

Source: [IBRANCE: Dose Monitoring During Treatment, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/monitoring#:~:text=Additional%20monitoring%20may%20be%20necessary%20based%20on%20the%20individual)

## Related pages
- [Medical information: Ibrance (palbociclib): All indications](https://www.evicenter.com/medical-information/ibrance)
- [Indication](https://www.evicenter.com/medical-information/ibrance/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ibrance/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/ibrance/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ibrance/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ibrance/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ibrance/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ibrance/access-and-coverage)
